Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice · 2025-01 · 13 (1) · 17-23
DOI: 10.1016/j.jaip.2024.08.025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025-01. Verfasst von Gunter J Sturm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria; Allergy Outpatient Clinic Reumannplatz, Vienna, Austria. Electro…. Hauptthemen laut MEDLINE: Insect Bites and Stings, Desensitization, Immunologic, Tryptases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergopharma, Novartis.
Abstract (Originalsprache)
Understanding the risk factors leading to severe systemic sting reactions (SSRs) is crucial for initiating venom immunotherapy (VIT) and for educating affected individuals and their families. Some of these risk factors are well established, some are no longer considered risk factors, and some remain controversial. Well-established risk factors for severe SSRs include clonal mast cell disease, high baseline serum tryptase, and advanced age. The absence of skin symptoms and the rapid onset of symptoms are indicators of severe SSRs. Recent publications indicate that antihypertensive treatment and stings in the head and neck area are not risk factors for severe SSRs. VIT is the only available treatment that can potentially prevent further anaphylactic reactions. Although rare and generally manageable, individuals undergoing VIT may experience systemic adverse events (sAEs). More sAEs are expected in patients undergoing bee VIT compared with vespid VIT. The role of elevated baseline serum tryptase as a risk factor for sAEs remains debated, but if it is a factor, the risk is increased by only about 1.5-fold. Rapid updosing protocols, depending on the specific regimen, can also be associated with more sAEs. Severe initial SSRs, antihypertensive medication, high skin test reactivity, and high specific IgE levels are not risk factors for sAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria; Allergy Outpatient Clinic Reumannplatz, Vienna, Austria. Electronic address: gunter.sturm@medunigraz.at.
- Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.
- Allergy Unit and Multidisciplinary Mastocytosis Outpatient Clinic, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
- University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Förderung
- Allergopharma
- Novartis
Zitieren
APA
Sturm, G. J., Schadelbauer, E., Marta, G., Bonadonna, P., & Kosnik, M. (2025). Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice, 13(1), 17-23. https://doi.org/10.1016/j.jaip.2024.08.025
Vancouver
Sturm GJ, Schadelbauer E, Marta G, Bonadonna P, Kosnik M. Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13(1):17-23. doi:10.1016/j.jaip.2024.08.025
BibTeX
@article{Sturm2025,
author = {Sturm, Gunter J and Schadelbauer, Eva and Marta, Giorgia and Bonadonna, Patrizia and Kosnik, Mitja},
title = {Risk Factors for Severe Sting Reactions and Side Effects During Venom Immunotherapy},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
volume = {13},
number = {1},
pages = {17--23},
doi = {10.1016/j.jaip.2024.08.025}
}
EUVIMED